News
HEPA
0.119
+24.49%
0.023
Weekly Report: what happened at HEPA last week (1109-1113)?
Weekly Report · 4d ago
Weekly Report: what happened at HEPA last week (1102-1106)?
Weekly Report · 11/09 09:03
Weekly Report: what happened at HEPA last week (1026-1030)?
Weekly Report · 11/02 09:03
Hepion Pharmaceuticals receives FDA feedback for GV104
TipRanks · 10/26 12:20
Weekly Report: what happened at HEPA last week (1019-1023)?
Weekly Report · 10/26 09:03
Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
Barchart · 10/26 07:01
Hepion Pharmaceuticals receives positive FDA response on GV104
TipRanks · 10/19 12:26
Weekly Report: what happened at HEPA last week (1012-1016)?
Weekly Report · 10/19 09:03
Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication
Barchart · 10/19 07:01
Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update
Barchart · 10/14 07:01
Weekly Report: what happened at HEPA last week (1005-1009)?
Weekly Report · 10/12 09:03
Hepion names new CEO as GLS acquisition closes
TipRanks · 10/09 21:03
Weekly Report: what happened at HEPA last week (0928-1002)?
Weekly Report · 10/05 09:03
Hepion Pharmaceuticals Expands Authorized Share Capital for Growth
TipRanks · 10/02 13:48
Weekly Report: what happened at HEPA last week (0921-0925)?
Weekly Report · 09/28 09:03
Weekly Report: what happened at HEPA last week (0914-0918)?
Weekly Report · 09/21 09:03
Weekly Report: what happened at HEPA last week (0907-0911)?
Weekly Report · 09/14 09:03
Hepion Pharmaceuticals Secures Funding via Convertible Note Agreement
TipRanks · 09/08 22:11
Weekly Report: what happened at HEPA last week (0831-0904)?
Weekly Report · 09/07 09:03
Weekly Report: what happened at HEPA last week (0824-0828)?
Weekly Report · 08/31 09:03
More
Webull provides a variety of real-time HEPA stock news. You can receive the latest news about Hepion Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About HEPA
Hepion Pharmaceuticals, Inc. is a biotechnology company developing a portfolio of diagnostic and therapeutic candidates for serious liver, immune, and inflammatory diseases. Through its subsidiary Gravitas Life Sciences, LLC, a clinical-stage biotechnology company, it is advancing therapeutic candidates in immunology and inflammation, including a transmucosal buccal film of an established opioid antagonist and an oral formulation of a validated anti-inflammatory antibody. Its diagnostic program is built on circulating tumor RNA technology, which reads actively expressed tumor transcripts for the early detection of hepatocellular carcinoma in high-risk cirrhotic patients, a cancer that is curable when found early. Its two licensed programs include GV104 and GV023. GV104 is a transmucosal buccal film of an approved opioid antagonist in clinical development for the temporary prophylaxis of respiratory and/or central nervous system depression. GV023 is an oral formulation of infliximab.